Skip to search formSkip to main contentSkip to account menu

Humira

National Institutes of Health

Related topics

Related topics

4 relations
0.2 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]0.4 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]0.8 ML adalimumab 50 MG/ML Injection [Humira]

Broader (1)

adalimumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A lack of evidence for six times more anxiety and depression in US graduate students than in the general population
2019
2019
Bringing Humira (Its Price) Down a Peg.
It's the best-selling drug by revenue worldwide and manufacturer AbbVie has worked hard to fend off competition. Very hard… 
Review
2018
Review
2018
Humira Patents Invalidated in Inter Partes Reviews
  • 2018
  • Corpus ID: 53498249
The Patent Trial and Appeal Board (PTAB) found all of the claims of three AbbVie Biotechnology Ltd. (AbbVie) patents directed to… 
2016
2016
Prescription of Brand-Name Medications When Generic Alternatives Are Available-Patently Unfair.
29. Siddiqui TCaZ. Ranbaxy gets FDA approval for Novartis’s Diovan generic. Reuters. June 27, 2014. http://in.reuters.com/article… 
Review
2015
Review
2015
FRI0115 Humira® (Adalimumab): Fifteen Years of Controlled Production and Consistency of Quality Attributes
Background Biologics, in particular monoclonal antibodies (mAbs), transformed treatment of autoimmune diseases such as rheumatoid… 
2014
2014
AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®
Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis… 
2014
2014
European Ombudsman ramps up action against European Medicines Agency over data transparency plans
The European Ombudsman has toughened her stance on the European Medicines Agency (EMA), after the agency failed to provide… 
2008
2008
Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)
2006
2006
Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010
Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market… 
2003
2003
Adalimumab (humira) for rheumatoid arthritis.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)